sound science sound science We’ve accelerated drug discovery through well-orchestrated research and sound science. We are on a mission to improve the lives of patients with over a dozen programs in our pipeline. Aria Pharmaceuticals is a preclinical-stage pharmaceutical company discovering and developing novel small molecule therapies for complex and hard-to-treat diseases. Too many patients […]
Total raised: $13.4M
Investors 4
| Date | Name | Website |
| - | CLI Ventur... | cli.ventur... |
| - | a16z | a16z.com/ |
| - | OS Fund | osfund.co |
| - | StartX | startx.com |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 19.03.2018 | Series A | $10M | a16z |
| 19.11.2015 | Seed | $3.4M | - |
Mentions in press and media 20
| Date | Title | Description |
| 26.03.2018 | This is how AI will shape drug discovery | An oft-quoted statistic is that it takes 12 years and almost $2 billion dollars to bring an average drug to market. That is the raison d’être for the biotech VC industry, which saw $10 billion of capital invested in startups in 2017 alone, ... |
| 19.03.2018 | twoXAR Raises $10M in Series A Financing | twoXAR, Inc., a Palo Alto, CA-based artificial intelligence (AI)-driven biopharmaceutical company, raised $10m in Series A financing. The round was led by SoftBank Ventures, with participation from Andreessen Horowitz Bio Fund and OS Fund. ... |
| 19.03.2018 | TwoXar raises $10 million from SoftBank, Andreessen Horowitz, and OS Fund to grow its AI drug discovery platform | Did you miss a session from GamesBeat Summit 2022? All sessions are available to stream now. Learn more. TwoXar, a biopharmaceutical startup that uses artificial intelligence (AI) to identify and develop new medicines, has raised $10 millio... |
| 19.03.2018 | SoftBank Ventures leads $10m Series A in AI biopharma startup twoXAR | Premium SoftBank Ventures, the early stage venture capital arm of Japan’s SoftBank Group, has led a $10-million Series A funding round of US-based artificial intelligence (AI)-driven biopharmaceutical firm twoXAR Inc. Continue reading this ... |
| 19.03.2018 | AI-Driven Drug Discovery Startup twoXAR Lands $10M for Computational Platform | twoXAR, Inc., an artificial intelligence (AI)-driven biopharmaceutical company, announced today that it has raised $10 million in Series A financing led by SoftBank Ventures including follow-on participation from seed investor Andreessen Ho... |
| 19.03.2018 | TwoXar raises $10 million from SoftBank, Andreessen Horowitz, and OS Fund to grow its AI drug discovery platform | TwoXar, a biopharmaceutical startup that uses artificial intelligence (AI) to identify and develop new medicines, has raised $10 million in a series A round of funding led by SoftBank’s early-stage venture capital firm, SoftBank Ventures, w... |
| 19.03.2018 | Term Sheet — Monday, March 19 | ANTITRUST SHOWDOWN Good morning, Term Sheet readers. Paid Content How can you protect what you can't see? From ExtraHop Here’s why this matters: • The merger fight has broad implications for various industries, specifically media and tech. ... |
| 19.03.2018 | Bioinformatics startup twoXAR bags $10M in Series A | JP Lee, managing director of SoftBank Ventures, will join Andreessen Horowitz general partner Vijay Pande on the twoXAR board of directors. Palo Alto, California-based twoXAR reached this next stage of growth thanks to $3.4 million in seed ... |
| 19.03.2018 | twoXAR Hauls in $10M Series A | PALO ALTO, CA, Artificial intelligence (AI)-driven biopharmaceutical company, announced today that it has raised $10 million in Series A financing led by SoftBank Ventures. >> Click here for more funding data on twoXAR >> To... |
| 19.03.2018 | Artificial intelligence firm twoXAR raises $10M for partnering drive | Artificial intelligence company twoXAR—a specialist in separating signals from noise in data-rich drug discovery projects—has raised $10 million in a first-round financing led by SoftBank Ventures. Co-founder and CEO Andrew Radin says the p... |
Show more